Description

EORTC ‘s research into adult Leukemia is mainly concerned with improving the outcomes of patients with leukemias or related hematologic malignancies. We operate through clinical trials, such as large standard-practice changing phase III studies, and run strong translational research programmes analysing epigenetic therapy in acute myeloid leukemia or myelodysplastic syndrome. EORTC works in collaboration with other national and international study groups, particularly the GIMEMA. We are also developing robust survivorship studies, taking advantage of the large number of patients already included in phase III research.

Main Achievements

Demonstrated the superiority of allogeneic vs autologous stem cell transplantation vs intensive consolidation in Acute Myeloid Leukemia (AML) younger patients More information

Showed high-dose cytarabine increased remission and survival rates as compared to standard-dose cytarabine, especially in AML patients younger than 46 years old More information

Found that first-line monotherapy with low-dose Gemtuzumab Ozogamicin, as compared with Best Supportive Care, significantly improved OS in older AML patients who were ineligible for intensive chemotherapy More information

Demonstrated decitabine administered in 6-week cycles is active in older patients with higher-risk MDS, resulting in improvements of OS and AMLFS (nonsignificant), of PFS and AML transformation (significant), and of QOL More information

Related Projects

  • RP-1479 (SPARTA): The Survivorship Project to understand and to improve long-Term outcomes for Acute myeloid leukemia patients.
    (Project leaders: F. Efficace / F. Baron)

The research project is ongoing.

Research Group

Group documents
  • Chair

    Frédéric Baron

    C.H.U. Sart-Tilman

    Liège, Belgium

  • Secretary

    Heiko Becker

    Universitaetsklinikum Freiburg

    Freiburg, Germany

  • Treasurer

    Laimonas Griskevicius

    Vilnius University Hospital Santariskiu Clinics

    Vilnius, Lithuania